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1.Introduction
Westernized countries face a growing burden of cardiovas-
cular diseases including acute complications of coronary
atherosclerosis. Cardiovascular diseases often associate with
metabolic disorders such as insulin resistance and obesity.
Emerging clinical and experimental studies suggest that
inﬂammation is central to the development of these car-
diometabolic disorders. A proinﬂammatory subset of mono-
cytes/macrophages may importantly contribute to patholog-
ical processes in cardiometabolic organs. Crosstalks between
cardiometabolic organs may enhance systemic and local
inﬂammatory milieu. In addition, accumulating evidence
supports a key role for inﬂammation in the pathogenesis of
vascular mineral deposition and calciﬁc aortic valve stenosis.
The goal of this special issue is to highlight what is known
concerning the inﬂammatory nature of cardiovascular dis-
eases, such as atherosclerosis and aortic valve calciﬁcation,
and their association with metabolic disorders. Armed
with this understanding, it is hoped that novel therapeutic
strategies will aid in the prevention and management of the
cardiometabolicsyndromeanditscomplications,andbeneﬁt
the patients aﬄicted with calciﬁc aortic valve disease.
2. Inﬂammationand MetabolicDiseases
Obesity, particularly visceral obesity, increases the clinical
risk of metabolic and cardiovascular diseases. In addition
to its function as a reservoir of lipids, adipose tissue is
now known to be an active endocrine organ that produces
a variety of “adipokines” and controls energy homeostasis.
It has been suggested that the dysregulated production of
proinﬂammatory mediators relative to the production of
anti-inﬂammatory adipokines (e.g., adiponectin) is an
important contributor to adverse metabolic and cardiovas-
cular consequences. Recent studies have also demonstrated
that the increased secretion of inﬂammatory mediators
seen in obese visceral fat reﬂects the ongoing chronic
inﬂammation of the adipose tissue, itself. The paper by V. Z.
Rocha and E.J. Folco and M. Itoh et al. deal with the molec-
ular mechanisms controlling adipose inﬂammation and the
systemic eﬀects of adipose inﬂammation on metabolic and
cardiovascular diseases. The paper by T. R. Aprahamian and
F. Sam focused on adiponectin. M. Furuhashi et al. reviewed
the functional involvement of fatty acid-binding proteins
in various cells in chronic diseases. These reviews provided
molecular insights into development of inﬂammation in
adiposetissueanditspropagationtodistanttissuesthatleads
to the development of cardiovascularand metabolic diseases.
3. Inﬂammation in Atherosclerosis
Inﬂammation contributes critically to all stages of athero-
genesis. Metabolic disorders such as dyslipidemia promote
activation of circulating monocytes and endothelial cells
and adhesion of these cell types, leading to accumulation
of macrophages. Macrophages then undergo activation and
produce proinﬂammatory cytokines and reactive oxygen
species. Oxidative stress activates neighboring cells including
endothelial cells and further promotes monocyte recruit-
ment. Such an uncontrolled ampliﬁcation mechanism rep-
resents inﬂammatory aspects of atherosclerosis. Naturally,
many studies have thus addressed whether antioxidants can
preventdevelopmentofatherosclerosisanditscomplications
and provided unsatisfactory results. In this special issue, F. J.
Pashkowoverviewedthisinterestingcontroversy.Accelerated2 International Journal of Inﬂammation
atherogenesis in patients with autoimmune disease has
long been recognized. E. Profumo et al. demonstrated that
oxidative stress links these two disorders. Accumulating
evidence suggested the causal role of endoplasmic reticulum
(ER) stress in apoptosis. But ER stress may also cause
various inﬂammatory disorders including atherosclerosis
and metabolic syndrome. T. Gotoh et al. discussed biology of
the ER stress pathway in atherogenesis and ischemic cardiac
injury. Inﬂammation not only promotes atherogenesis but
also may trigger acute onset of its clinical complication such
as coronary thrombosis by reducing mechanical stability of
the plaque. D. Segers et al. demonstrated the role of the
chemokine CXCL10 in decreased plaque stability as gauged
by collagen loss in mouse and human atherosclerotic lesions.
4. InﬂammationinCardiacRemodeling
Regardless of the origin, injury to the heart evokes a diverse
and complex array of cellular responses involving both
cardiomyocytes and nonmuscle cells that initiate and sustain
a process of structural remodeling of the myocardium.
Remodeling of the myocardium is a key determinant of
the clinical course of heart failure. Many of the processes
underlying cardiac remodeling have features in common
with chronic inﬂammatory processes. In this issue, the
paper by N. Takeda and I. Manabe and Y. Yoshimatsu
and T. Watabe reviewed cellular and molecular processes
underlying cardiac ﬁbrosis and remodeling. The former
paper focuses on the involvement of noncardiomyocytes,
highlighting the dynamic cellular interplays in cardiac
remodeling. The latter deals with endothelial-mesenchymal
transition (EMT), suggesting the endothelial origin of a
subset of cardiac ﬁbroblasts. The paper by Y. Feng and W.
Chao reviewed the involvement of Toll-like receptors (TLRs)
in myocardial responses to infarction and sepsis. TLRs are
the major pattern recognition receptors that detect not only
the pathogen-associated molecular patterns (PAMPs), but
also the damage-associated molecular patterns (DAMPs),
including a variety of endogenous molecules. As reviewed in
M. Itoh et al., TLRs have also been shown to be important
foractivationofinﬂammatoryprocessesinmetabolictissues.
These paper provide some of the key ideas in the emerging
ﬁeld of cardiac biology.
5. Cardiac Valve Inﬂammation
It is now widely accepted that inﬂammatory mechanisms
also play a role in development of aortic stenosis. Aortic
stenosis shares some risk factors and characteristics with
those of atherosclerosis, but remains relatively less amenable
to pharmacological intervention. Diﬀerences in the aetiology
of the diﬀerent disease process may be a reﬂection of the
unique mechanical environment in which the aortic valve
resides. The papers in this special issue that focus on heart
valves illustrate the important role inﬂammatory mediators
play in the development, tissue remodeling, and repair of the
valve, as well as the initiation and progression of the disease
process.ThepaperbyG.J.MahlerandJ.T.Butcherexamined
the role of inﬂammatory mediators from development to
disease. Their paper illustrated how mediators such as TGF-
β,T N F - α, and BMPs play an important role in the self-
repair and tissue-remodeling properties that help maintain
the durability and strength of the valve. The role of changes
in the diﬀerent types of mechanical force to which the aortic
valve is exposed is discussed by K. Balachandran et al. and,
more speciﬁcally, J. N. Warnock et al. presented new data on
the inﬂuence of increased levels of pressure in inﬂammatory
gene networks.
We will only then be able to identify targets that might be
amenable to molecular or pharmacological modulation after
we have gained a comprehensive understanding of the genes
expressed,themoleculesreleased,andthesignalingpathways
activated during the onset and progression of aortic stenosis.
While work with animal and human cells and tissue is an
important stepinthisprocess,development ofrobustanimal
models that recapitulates the human disease process will be
fundamental to assaying the eﬃcacy of new interventions.
In this regard, K. L. Sider and colleagues provided a
comprehensive summary of the currently available animal
models of aortic stenosis.
6. Conclusion
The cardiometabolic syndrome represents a global health
burden. An emerging concept suggests that inﬂammation
participates in the pathogenesis of cardiometabolic disorders
including atherosclerosis, obesity, insulin resistance, and
aortic valve disease. Thus, controlling proinﬂammatory
molecules or pathways may attenuate such diseases. The goal
of this thematic series is to highlight what is known con-
cerning the role inﬂammation plays in the cardiometabolic
syndrome and what the therapeutic options are. We believe
that this issue will oﬀer updated concepts and help readers
develop ideas leading to future investigations and new drug
development.
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